MARC Record from harvard_bibliographic_metadata

LEADER: 02157cam a2200493 a 4500
001 012627200-X
005 20120815145116.0
008 100819s2010 bcc b 001 0 eng
016 $a20109048784
020 $a9781553655084
020 $a1553655087
035 0 $aocn555627797
040 $aNLC$beng$cNLC$dBTCTA$dYDXCP$dVP@$dCDX$dORX$dUUS$dEDX$dCOU
050 4 $aHD9665.5$b.M692 2010
055 0 $aHD9665.5$bM692 2010
082 04 $a381/.456151$222
100 1 $aMoynihan, Ray.
245 10 $aSex, lies, + pharmaceuticals :$bhow drug companies plan to profit from female sexual dysfunction /$cRay Moynihan and Barbara Mintzes.
246 3 $aSex, lies, and pharmaceuticals
260 $aVancouver :$bGreystone Books,$cc2010.
300 $axi, 257 p. ;$c22 cm.
504 $aIncludes bibliographical references (p. 223-242) and index.
505 0 $aDifficulties or dysfunctions? -- 43 per cent -- Measuring pleasure -- Educating doctors with ski trips and strip clubs -- Viagra turns twelve -- Premature prescriptions -- Undoing the disorders -- Looking ahead.
520 $aaReveals how womens' sexual difficulties are being repackaged as symptoms of a new disorder and investigates the creation of female sexual dysfunction or FSD, and the marketing machine that promises to "cure" it.
650 0 $aDrugs and sex.
650 0 $aSexual disorders$xEconomic aspects.
650 0 $aDrugs$xMarketing.
650 0 $aAdvertising$xDrugs.
650 0 $aPharmaceutical industry.
650 12 $aDrug Industry$xeconomics.
650 12 $aMarketing of Health Services$xeconomics.
650 12 $aSexual Dysfunction, Physiological$xdrug therapy.
650 22 $aSexual Dysfunctions, Psychological$xdrug therapy.
650 22 $aGenital Diseases, Female$xeconomics.
650 22 $aConflict of Interest$xeconomics.
650 0 $aPharmaceutical industry$xMoral and ethical aspects.
650 0 $aPharmaceutical industry$xEconomic aspects.
650 0 $aSexual desire disorders$xEconomic aspects.
650 0 $aWomen$xSexual behavior.
700 1 $aMintzes, Barbara.
899 $a415_565553
988 $a20101202
049 $aCLSL
906 $0OCLC